Sublicensing Agreement with Regard to the Use of RIKEN Mouse FANTOM™ cDNA Clones (Slant DNA, Clone Set)Sublicensing Agreement • October 13th, 2016
Contract Type FiledOctober 13th, 2016To K.K. DNAFORM, the Sublicensor (hereafter the "Sublicensor") for the right to the use of RIKEN Mouse FANTOM™ cDNA Clones and the related information thereof possessed by The Institute of Physical and Chemical Research (RIKEN).
AGREEMENTSublicensing Agreement • October 4th, 2000 • Adept Technology Inc • Special industry machinery, nec
Contract Type FiledOctober 4th, 2000 Company Industry
Sublicensing Agreement Between Aidan, Incorporated and BioPulse International, Inc. Sublicensing Agreement between Aidan, Incorporated and BioPulse International, Inc.Sublicensing Agreement • December 21st, 2000 • Bio Pulse International Inc • Services-social services • Arizona
Contract Type FiledDecember 21st, 2000 Company Industry Jurisdiction
Exhibit 10.14 SUBLICENSING AGREEMENT This SUBLICENSING AGREEMENT ("Agreement") is made this __ day of January, 2000, (the "Effective Date") by and between The BigHub.com, Inc., a Florida corporation ("Company") and Interplanner.com Inc., a Florida...Sublicensing Agreement • January 28th, 2000 • Bighub Com Inc • Services-business services, nec
Contract Type FiledJanuary 28th, 2000 Company Industry
ContractSublicensing Agreement • January 13th, 2017
Contract Type FiledJanuary 13th, 2017
Sublicensing Agreement with the end user of arthroprosthesis templatesSublicensing Agreement • August 6th, 2020
Contract Type FiledAugust 6th, 2020
SUB-LICENSING AGREEMENTSublicensing Agreement • October 29th, 2018 • OSI ETF Trust
Contract Type FiledOctober 29th, 2018 CompanyThis AGREEMENT, dated as of May 23, 2018 by and among O'Shares Investments Inc., a Canadian corporation ("O'Shares"), and OSI ETF Trust, a Delaware statutory trust (the "Trust") that is registered as an open-end management investment company under the Investment Company Act of 1940, as amended (the "1940 Act"), on behalf of certain series of the Trust identified on Exhibit A, as it may be amended from time to time (each, a "Fund" and, collectively, the "Funds").
SUBLICENSING AGREEMENT dated ……. PartiesSublicensing Agreement • January 27th, 2022
Contract Type FiledJanuary 27th, 2022The Sublicensee acknowledges and agrees that the original or a counterpart of this Sublicensing Agreement can be handed over to the xxxxxx at any time, during the duration or even after the termination of this Agreement.
Viaplay Group and Baltic media company TV3 Group have signed an agreement covering Estonia, Latvia and Lithuania. Starting 1 February, Viaplay’s full live sports portfolio in the Baltic region will be sublicensed to TV3 Group’s streaming service Go3,...Sublicensing Agreement • January 31st, 2024
Contract Type FiledJanuary 31st, 2024Jørgen Madsen Lindemann, Viaplay Group President and CEO: “This is the right step for Viaplay Group’s business and for our sports viewers across the Baltic region. It enables us to sharpen our operational focus even further on the Nordics, Netherlands and Viaplay Select, which are the markets where we see the best conditions for growth and profitability, as well as on Poland, where we will operate until mid-2025. At the same time, our sports content in Estonia, Latvia and Lithuania will be available through a well- established platform operated by a local group.”
ContractSublicensing Agreement • April 2nd, 2018
Contract Type FiledApril 2nd, 2018Sysmex and ImmuniT Research Enter Agreement on the Sublicensing of a Patent Related to a Diagnosing Method for Predicting Efficacy of Immune Checkpoint Inhibitors
SUBLICENSING AGREEMENTSublicensing Agreement • February 9th, 2023
Contract Type FiledFebruary 9th, 2023XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX.